Cell Therapy News/Articles, page-9630

Hey, yes, I think that I pointed out that opioids is the hotspot right now and that MSBs rex has a great treatment for that hotspot, when I posted this article?

https://www.politico.com/news/2021/06/11/fda-woodcock-controversial-drug-approval-493324

Manchin's calling for Woodcocks removal, with the opioids as his hotspot outside of Aduhelm, too:

https://www.fiercepharma.com/pharma/sen-manchin-calls-for-woodcock-s-removal-as-fda-fallout-from-biogen-alzheimer-s-approval

To be sure, the Aduhelm approval isn’t the only issue the West Virginia senator has taken up with Woodcock. Manchin, along with six other Democrat and Independent senators, called on Biden earlier this year to institute new FDA leadership to address the ongoing opioid crisis. In Manchin’s Thursday letter, the senator said Woodcock has “shown a dereliction of duty by not working to end” the opioid epidemic.

Now, interestingly, the FDA just released its proposed 2022 budget, and its focussed squarely on the crisis (opioid not covid..):

https://www.fda.gov/news-events/fda-voices/fdas-budget-advancing-goal-ending-opioid-crisis

Of the below, I particularly liked 3, for some reason..

Addressing Priority Areas and Developing New Treatments

As part of broad cross-government efforts, the FDA is committed to examining all facets of opioid abuse, misuse, addiction, overdose and death in the U.S. The agency is taking steps to address four priority areas to address the crisis: (1) decreasing exposure and preventing new addiction; (2) supporting the treatment of those with opioid use disorder (OUD); (3) fostering the development of novel non-opioid pain treatment therapies; and (4) improving enforcement and assessing benefit-risk.

What @What ?!